Literature DB >> 25499715

Limb salvage after vascular reconstruction followed by tissue transfer during the Global War on Terror.

Kevin Casey1, Jennifer Sabino2, Jeffrey S Weiss3, Anand Kumar4, Ian Valerio5.   

Abstract

BACKGROUND: Combat extremity wounds are complex and frequently require an immediate vascular reconstruction in the operational environment followed by delayed tissue coverage at a stateside medical treatment facility. The purpose of this study was to evaluate limb salvage outcomes after combat-related vascular reconstruction that subsequently required delayed soft tissue coverage during the Global War on Terror.
METHODS: Patients who incurred a war-related extremity injury necessitating an immediate vascular intervention followed by definitive limb reconstruction requiring flap coverage from combat injuries were reviewed. Patient demographics, types of vascular and extremity injuries, and surgical interventions were examined. Outcomes included limb salvage, primary and secondary graft patency, flap outcomes, and complications. Differences between upper extremities (UEs) and lower extremities (LEs) were compared.
RESULTS: From 2003 to 2012, 27 patients were treated for combat-related extremity injuries with an immediate vascular reconstruction followed by delayed tissue coverage. Fifteen LEs and 12 UEs were treated. The mean age was 24 years. An explosion was the cause in 77% of patients, with a mean Injury Severity Score (ISS) of 19. An autogenous vein bypass was the most common reconstruction performed in 20 patients (74%). Other vascular repairs included a primary repair, a patch angioplasty with bovine pericardium, and a bypass with use of a prosthetic graft. Eight patients (30%) had a concomitant venous injury, and 23 (85%) had a bone fracture. Thirty flaps were performed at a mean of 33 days from the original injury. Pedicle flaps were used in 24 limbs and free tissue flaps in six limbs. Muscle, fasciocutaneous, bone, and composite flaps were used for tissue coverage. At a mean follow-up of 16 months, primary patency rates of all arterial reconstructions were 66% in the UE and 53% in the LE (P = .69). Secondary patency rates were 100% in the UE and 86% in the LE (P = .48). The overall limb salvage rate was 81%. Limb salvage rates were 66% in the LE and 100% in the UE (P = .04). Three amputated lower limbs (60%) had inline flow to the foot. The flap success rate was 96%. Reasons for amputation included arterial thrombosis, flap failure, persistent soft tissue infection, osteomyelitis, and debilitating peripheral nerve injuries with associated chronic pain.
CONCLUSIONS: Immediate vascular repair followed by delayed tissue coverage can be performed with a high (>80%) limb salvage rate after combat trauma. Limb salvage rates were higher in the UE despite equivocally high arterial patency rates. Wounded warriors can expect limb salvage by use of this international algorithm. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2014        PMID: 25499715     DOI: 10.1016/j.jvs.2014.10.039

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  4 in total

1.  Brachial artery protected by wrapped latissimus dorsi muscle flap in high voltage electrical injury.

Authors:  E Gencel; C Eser; O Kokacya; E Kesiktas; M Yavuz
Journal:  Ann Burns Fire Disasters       Date:  2016-06-30

2.  Microsurgical free muscle flaps for reconstruction of post-traumatic complex tissue defects of foot.

Authors:  B K Varghese; P Babu; T Roy
Journal:  Med J Armed Forces India       Date:  2016-04-16

3.  Embryonic Stem Cells-loaded Gelatin Microcryogels Slow Progression of Chronic Kidney Disease.

Authors:  Xiao-Dong Geng; Wei Zheng; Cong-Mei Wu; Shu-Qiang Wang; Quan Hong; Guang-Yan Cai; Xiang-Mei Chen; Di Wu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

4.  Mesenchymal Stem Cells Loaded with Gelatin Microcryogels Attenuate Renal Fibrosis.

Authors:  Xiaodong Geng; Quan Hong; Kun Chi; Shuqiang Wang; Guangyan Cai; Di Wu
Journal:  Biomed Res Int       Date:  2019-10-31       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.